Latest Administration News

Nexsen Limited has initiated clinical trials for its StrepSure® GBS Rapid Sensor, a next-generation diagnostic device aimed at improving maternal health outcomes. The trial's success could pave the way for regulatory approval and early market penetration by the second half of 2026.

Praemium reported a robust start to FY2026 with total Funds Under Administration rising 13% to $67 billion, led by strong organic growth in its Spectrum platform. The company’s strategic focus on high-net-worth clients and platform consolidation continues to gain traction.

HUB24 has reported a record $5.2 billion in net inflows for Q1 FY26, boosting its Funds Under Administration to $146.5 billion and securing the top spot for adviser satisfaction in Australia.

Connected Minerals reports strong uranium grades from its Etango North-East Project in Namibia and progresses rare earth exploration plans in Western Australia, maintaining a solid financial footing.

Prominence Energy has extended its agreement to acquire the Gawler Hydrogen Project, allowing more time to secure final regulatory approvals and advance exploration in South Australia.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

Avira Resources has secured a binding agreement to acquire the high-grade Mt Cattlin Gold Project in Western Australia, backed by a $2.5 million capital raise to advance exploration and resource development.

Scout Security has raised a further $220,000 through a share placement, bringing total capital raised to $820,000, as it works toward resolving its trading suspension.

True North Copper has appointed Andrew Mooney as Managing Director, signaling a strategic shift towards advanced exploration and project development in Queensland.

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.

Perpetual Limited reported a robust first quarter for FY26, with growth across its Asset Management, Corporate Trust, and Wealth Management divisions, driven by strong market returns and strategic initiatives.

Actinogen Medical has fast-tracked recruitment in its XanaMIA Alzheimer’s trial, closing pTau biomarker screening early and increasing participant numbers, aiming for final results by mid Q4 2026.